Nevirapine Vocate

Nevirapine, the active ingredient in Nevirapine Vocate, is a Non‑nucleoside reverse transcriptase inhibitor (NNRTI) presented as a tablet for oral use. It is used to treat HIV‑1 infection in adults and children as part of combination antiretroviral therapy.

GNH USA supplies Nevirapine Vocate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nevirapine is an antiretroviral drug that targets HIV‑1 reverse transcriptase, a key enzyme in the viral replication cycle. - HIV‑1 infection: reduces plasma viral load when used in combination with other antiretrovirals. - Pediatric HIV‑1 infection: provides viral suppression in children as part of age‑appropriate regimens. - Treatment‑experienced HIV patients: offers an alternative NNRTI option for those with prior therapy exposure.

Nevirapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Rash: mild to moderate skin eruptions. - Nausea: occasional gastrointestinal discomfort. - Fatigue: general feeling of tiredness. - Headache: transient cranial pain. - Insomnia: difficulty falling or staying asleep. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe mucocutaneous reaction. - Hepatotoxicity: elevated liver enzymes or liver failure. - Severe skin reactions: toxic epidermal necrolysis. - Hypersensitivity syndrome: fever, rash, organ involvement. - Hepatic necrosis: rare but life‑threatening liver injury. - Anaphylaxis: acute allergic response requiring immediate care.

Before initiating therapy, clinicians should assess patient history and monitor for potential risks. - Liver function monitoring: perform baseline and periodic liver enzyme tests. - Rash assessment: examine skin regularly for early signs of severe reactions. - Avoid concurrent potent CYP3A inducers: may reduce nevirapine exposure. - Caution in hepatitis B/C co‑infection: increased risk of liver toxicity. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Nevirapine interacts with several medicines that affect its metabolism or increase toxicity.

Major Interactions (Avoid): - Rifampicin: strong CYP3A inducer that markedly lowers nevirapine levels. - St. John’s wort: herbal CYP3A inducer reducing efficacy. - Carbamazepine: enzyme inducer leading to subtherapeutic concentrations. - Phenytoin: reduces nevirapine exposure via hepatic induction. - Efavirenz: concurrent NNRTIs may increase toxicity.

Moderate Interactions (Monitor Closely): - Ritonavir-boosted protease inhibitors: may increase nevirapine plasma levels. - Azole antifungals (e.g., fluconazole): can raise nevirapine concentrations. - Oral contraceptives: nevirapine may reduce hormonal efficacy; consider alternative contraception. - Methadone: may require dose adjustment due to altered metabolism. - Anti‑tuberculosis drugs (excluding rifampicin): monitor liver function closely.